ASND

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Ascendis Pharma AS

NASDAQ | ASND

197.75

USD

$0.00

(

0.00%

)

At Close (As of Nov 5, 2025)

$12.61B

Market Cap

-

P/E Ratio

-5.23

EPS

$216.45

52 Week High

$118.03

52 Week Low

HEALTHCARE

Sector

ASND Chart

Recent Chart
Price Action

ASND Technicals

Tags:

ASND Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (EUR)
Gross Profit $319M
Total Revenue $364M
Cost Of Revenue $44M
Costof Goods And Services Sold $44M
Operating Income -$279M
Selling General And Administrative $285M
Research And Development $307M
Operating Expenses $598M
Investment Income Net -
Net Interest Income -$51M
Interest Income $14M
Interest Expense $66M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $18M
Income Before Tax -$373M
Income Tax Expense $4.8M
Interest And Debt Expense -
Net Income From Continuing Operations -$378M
Comprehensive Income Net Of Tax -
Ebit -$308M
Ebitda -$290M
Net Income -$378M

Revenue & Profitability

Earnings Performance

ASND Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (EUR)
Total Assets $1.2B
Total Current Assets $1.1B
Cash And Cash Equivalents At Carrying Value $560M
Cash And Short Term Investments $560M
Inventory $296M
Current Net Receivables $166M
Total Non Current Assets $119M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $533K
Intangible Assets Excluding Goodwill $533K
Goodwill $3.5M
Investments -
Long Term Investments $14M
Short Term Investments $0
Other Current Assets $39M
Other Non Current Assets -
Total Liabilities $1.3B
Total Current Liabilities $908M
Current Accounts Payable $96M
Deferred Revenue -
Current Debt -
Short Term Debt $492M
Total Non Current Liabilities $377M
Capital Lease Obligations -
Long Term Debt $365M
Current Long Term Debt $492M
Long Term Debt Noncurrent -
Short Long Term Debt Total $857M
Other Current Liabilities $318M
Other Non Current Liabilities -
Total Shareholder Equity -$106M
Treasury Stock -
Retained Earnings -$2.6B
Common Stock $8.1M
Common Stock Shares Outstanding $58M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (EUR)
Operating Cashflow -$306M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $18M
Capital Expenditures $1.4M
Change In Receivables -
Change In Inventory -$87M
Profit Loss -
Cashflow From Investment $6.9M
Cashflow From Financing $444M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity $0
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$378M

yearly Income Statement (As of Dec 31, 2024)

Field Value (EUR)
Gross Profit $319M
Total Revenue $364M
Cost Of Revenue $44M
Costof Goods And Services Sold $44M
Operating Income -$279M
Selling General And Administrative $285M
Research And Development $307M
Operating Expenses $598M
Investment Income Net -
Net Interest Income -$51M
Interest Income $14M
Interest Expense $66M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $18M
Income Before Tax -$373M
Income Tax Expense $4.8M
Interest And Debt Expense -
Net Income From Continuing Operations -$378M
Comprehensive Income Net Of Tax -
Ebit -$308M
Ebitda -$290M
Net Income -$378M

ASND News

ASND Profile

Ascendis Pharma AS Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Ascendis Pharma A/S is a biopharmaceutical innovator based in Hellerup, Denmark, dedicated to creating transformative therapies for significant unmet medical needs in various therapeutic areas, particularly rare diseases and endocrine disorders. Leveraging its proprietary TransConâ„¢ technology platform, the company is actively advancing a promising pipeline of product candidates through rigorous clinical trials. Ascendis is focused not only on developing groundbreaking treatments but also on establishing a sustainable business model that prioritizes patient health and supports long-term growth initiatives.

CHR
-45.58%
$0.07
NVVE
-8.57%
$0.19
MTC
+626.97%
$2.21
ASST
+16.80%
$1.46
RIVN
+23.36%
$15.42
LNAI
+40.28%
$1.17
NVDA
-1.75%
$195.21
GPUS
+11.61%
$0.39
PFE
+1.27%
$24.61
RUBI
-49.75%
$0.30
VHAI
0.00%
$0.00
BYND
-4.51%
$1.27
PLUG
+4.76%
$2.64
SNAP
-2.27%
$7.30
TSLA
+4.00%
$462.07
GRAB
-2.50%
$5.64
YDKG
-5.55%
$0.05
SLDP
+51.55%
$8.51
F
+2.50%
$13.11
SMX
+43.53%
$2.11
PLTR
-1.48%
$187.90
PINS
-21.75%
$25.75
INTC
+3.64%
$38.38
DNN
-2.55%
$2.67
AXDX
-61.36%
$0.03
AMD
+2.51%
$256.33
ACHR
+0.10%
$9.57
T
+0.49%
$24.56
AAL
+6.08%
$13.42
SMCI
-11.32%
$42.03
BITF
+5.72%
$4.05
KVUE
+1.62%
$16.23
ONDS
+0.67%
$6.00
WTO
-0.20%
$0.04
CIFR
+9.77%
$24.71
SOFI
+2.38%
$30.07
RXRX
-0.80%
$4.96
TEVA
+20.23%
$24.60
BAC
-2.03%
$52.45
NFE
+10.37%
$1.49
ETHD
-14.82%
$4.48
ADAP
-15.14%
$0.05
AMCR
+2.54%
$8.07
DVLT
-10.11%
$1.60
BTG
+0.75%
$4.03
WBD
+0.70%
$22.76
IREN
+14.67%
$76.41
MARA
+3.06%
$17.13
VALE
+3.09%
$12.31
QS
+10.55%
$17.07
AAPL
+0.03%
$270.14
RIG
0.00%
$3.90
CAN
+16.21%
$1.29
U
+18.09%
$42.36
RGTI
+5.99%
$37.29
RMBL
+60.50%
$3.21
WULF
+2.33%
$15.36
FUBO
+10.86%
$4.08
AMZN
+0.35%
$250.20
ADD
-25.47%
$0.05
BURU
+0.20%
$0.29
NVO
+0.43%
$48.46
EPWK
-6.41%
$0.07
TLRY
+3.22%
$1.28
HIMS
+2.19%
$43.73
BTBT
+3.14%
$3.28
SRM
+53.27%
$10.30
NIO
+1.81%
$7.29
PCG
+0.68%
$16.27
BMNR
+4.96%
$41.42
NCLH
-0.95%
$18.61
ZDAI
+13.94%
$0.52
RIOT
-1.58%
$18.97
JOBY
+1.62%
$15.00
NOK
+0.58%
$6.85
HTZ
-0.81%
$6.67
APPS
+23.14%
$7.29
CMG
+0.72%
$31.97
ALIT
-7.03%
$2.50
QBTS
+4.30%
$31.02
NGD
+2.40%
$6.80
GOOGL
+2.43%
$284.31
HOOD
+4.15%
$142.47
BBD
+3.62%
$3.53
BW
+28.34%
$4.80
NVTS
-5.73%
$9.86
WLGS
-5.57%
$0.04
MU
+8.93%
$237.50
IONZ
-7.60%
$4.13
SOUN
+3.89%
$15.72
HPE
+0.63%
$23.71
AG
-7.69%
$10.67
RDHL
+2.77%
$1.11
PLTZ
+2.80%
$6.24
GGB
+5.26%
$3.60
ETWO
0.00%
$3.30
HBAN
+0.13%
$15.29
CPNG
-5.94%
$30.22
PBR
+2.62%
$12.14
ABEV
+1.25%
$2.42
CHR
-45.58%
$0.07
NVVE
-8.57%
$0.19
MTC
+626.97%
$2.21
ASST
+16.80%
$1.46
RIVN
+23.36%
$15.42
LNAI
+40.28%
$1.17
NVDA
-1.75%
$195.21
GPUS
+11.61%
$0.39
PFE
+1.27%
$24.61
RUBI
-49.75%
$0.30
VHAI
0.00%
$0.00
BYND
-4.51%
$1.27
PLUG
+4.76%
$2.64
SNAP
-2.27%
$7.30
TSLA
+4.00%
$462.07
GRAB
-2.50%
$5.64
YDKG
-5.55%
$0.05
SLDP
+51.55%
$8.51
F
+2.50%
$13.11
SMX
+43.53%
$2.11
PLTR
-1.48%
$187.90
PINS
-21.75%
$25.75
INTC
+3.64%
$38.38
DNN
-2.55%
$2.67
AXDX
-61.36%
$0.03
AMD
+2.51%
$256.33
ACHR
+0.10%
$9.57
T
+0.49%
$24.56
AAL
+6.08%
$13.42
SMCI
-11.32%
$42.03
BITF
+5.72%
$4.05
KVUE
+1.62%
$16.23
ONDS
+0.67%
$6.00
WTO
-0.20%
$0.04
CIFR
+9.77%
$24.71
SOFI
+2.38%
$30.07
RXRX
-0.80%
$4.96
TEVA
+20.23%
$24.60
BAC
-2.03%
$52.45
NFE
+10.37%
$1.49
ETHD
-14.82%
$4.48
ADAP
-15.14%
$0.05
AMCR
+2.54%
$8.07
DVLT
-10.11%
$1.60
BTG
+0.75%
$4.03
WBD
+0.70%
$22.76
IREN
+14.67%
$76.41
MARA
+3.06%
$17.13
VALE
+3.09%
$12.31
QS
+10.55%
$17.07
AAPL
+0.03%
$270.14
RIG
0.00%
$3.90
CAN
+16.21%
$1.29
U
+18.09%
$42.36
RGTI
+5.99%
$37.29
RMBL
+60.50%
$3.21
WULF
+2.33%
$15.36
FUBO
+10.86%
$4.08
AMZN
+0.35%
$250.20
ADD
-25.47%
$0.05
BURU
+0.20%
$0.29
NVO
+0.43%
$48.46
EPWK
-6.41%
$0.07
TLRY
+3.22%
$1.28
HIMS
+2.19%
$43.73
BTBT
+3.14%
$3.28
SRM
+53.27%
$10.30
NIO
+1.81%
$7.29
PCG
+0.68%
$16.27
BMNR
+4.96%
$41.42
NCLH
-0.95%
$18.61
ZDAI
+13.94%
$0.52
RIOT
-1.58%
$18.97
JOBY
+1.62%
$15.00
NOK
+0.58%
$6.85
HTZ
-0.81%
$6.67
APPS
+23.14%
$7.29
CMG
+0.72%
$31.97
ALIT
-7.03%
$2.50
QBTS
+4.30%
$31.02
NGD
+2.40%
$6.80
GOOGL
+2.43%
$284.31
HOOD
+4.15%
$142.47
BBD
+3.62%
$3.53
BW
+28.34%
$4.80
NVTS
-5.73%
$9.86
WLGS
-5.57%
$0.04
MU
+8.93%
$237.50
IONZ
-7.60%
$4.13
SOUN
+3.89%
$15.72
HPE
+0.63%
$23.71
AG
-7.69%
$10.67
RDHL
+2.77%
$1.11
PLTZ
+2.80%
$6.24
GGB
+5.26%
$3.60
ETWO
0.00%
$3.30
HBAN
+0.13%
$15.29
CPNG
-5.94%
$30.22
PBR
+2.62%
$12.14
ABEV
+1.25%
$2.42
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.